- Home
- SEZL vs BLFS Comparison
SEZL vs BLFS Comparison
Compare SEZL & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- BLFS
- Stock Information
- Founded
- SEZL 2016
- BLFS 1987
- Country
- SEZL United States
- BLFS United States
- Employees
- SEZL N/A
- BLFS N/A
- Industry
- SEZL Diversified Financial Services
- BLFS Medical/Dental Instruments
- Sector
- SEZL Finance
- BLFS Health Care
- Exchange
- SEZL Nasdaq
- BLFS Nasdaq
- Market Cap
- SEZL 4.4B
- BLFS 1.0B
- IPO Year
- SEZL N/A
- BLFS 1989
- Fundamental
- Price
- SEZL $181.87
- BLFS $22.84
- Analyst Decision
- SEZL Strong Buy
- BLFS Strong Buy
- Analyst Count
- SEZL 3
- BLFS 7
- Target Price
- SEZL $108.28
- BLFS $30.57
- AVG Volume (30 Days)
- SEZL 1.1M
- BLFS 658.4K
- Earning Date
- SEZL 08-06-2025
- BLFS 08-07-2025
- Dividend Yield
- SEZL N/A
- BLFS N/A
- EPS Growth
- SEZL 677.39
- BLFS N/A
- EPS
- SEZL 2.97
- BLFS N/A
- Revenue
- SEZL $329,060,890.00
- BLFS $87,762,000.00
- Revenue This Year
- SEZL $66.19
- BLFS $21.21
- Revenue Next Year
- SEZL $25.26
- BLFS $17.58
- P/E Ratio
- SEZL $61.36
- BLFS N/A
- Revenue Growth
- SEZL 91.69
- BLFS 34.80
- 52 Week Low
- SEZL $11.67
- BLFS $18.70
- 52 Week High
- SEZL $182.49
- BLFS $29.55
- Technical
- Relative Strength Index (RSI)
- SEZL 74.42
- BLFS 57.04
- Support Level
- SEZL $161.44
- BLFS $21.13
- Resistance Level
- SEZL $181.94
- BLFS $22.07
- Average True Range (ATR)
- SEZL 11.47
- BLFS 0.91
- MACD
- SEZL 1.10
- BLFS 0.13
- Stochastic Oscillator
- SEZL 99.36
- BLFS 88.73
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, primarily deriving revenue from payment processing platform in North America.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.